Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Interventions
LP-118
Drug
Lead sponsor
Newave Pharmaceutical Inc
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more
Conditions
Multiple Myeloma
Interventions
First-line therapy, Second-line Multiple Myeloma treatments
Other · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
3,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
252
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more
Conditions
Multiple Myeloma
Interventions
Mapatumumab, Bortezomib
Biological · Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • La Jolla, California • Lecanto, Florida + 5 more
Conditions
Sedentary Behavior, Insulin Sensitivity, Sedentary Lifestyle
Interventions
SIT, ACTIVE, EX
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Completed Phase 2 Interventional Results available

Daratumumab in Treating Patients With Multiple Myeloma

NCT02944565
Conditions
Plasma Cell Myeloma
Interventions
Daratumumab
Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Elective Foot and Ankle Surgery.
Interventions
PRP and PPP
Biological
Lead sponsor
Gary M. Kiebzak, Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Coral Gables, Florida
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Carfilzomib, Dexamethasone, Lenalidomide (Control)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Detroit, Michigan
Conditions
Multiple Myeloma
Interventions
LBH589, Lenalidomide
Drug · Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • New York, New York
Conditions
Multiple Myeloma
Interventions
Etentamig (ABBV-383)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 21 more
Conditions
Multiple Myeloma, Lymphoma, Transplant-Related Disorder
Interventions
Feedback
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests

NCT04375982
Conditions
Embolism and Thrombosis, Infection, Inflammation
Interventions
Venepuncture, Fingerstick
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Banning, California • Northglenn, Colorado • Wichita, Kansas + 1 more
Conditions
Femoroacetabular Impingement, Chondral Lesions
Interventions
Platelet-rich plasma (PRP), Saline
Biological · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boulder, Colorado
Conditions
Multiple Myeloma
Interventions
Placebo, Velcade and dexamethasone, Siltuximab, Velcade and dexamethasone
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Iowa City, Iowa • Boston, Massachusetts • Toledo, Ohio + 2 more
Conditions
Multiple Myeloma, Fatigue
Interventions
AYO light glasses (Experimental), AYO light glasses (Comparator)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
recombinant interferon-α, recombinant interleukin-6
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
Conditions
Multiple Myeloma
Interventions
Nivolumab
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
Talquetamab, Mezigdomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
3
States / cities
Chicago, Illinois • Cleveland, Ohio
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bevacizumab, thalidomide
Biological · Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 1 more
Conditions
Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more
Conditions
Dry Eye Syndromes
Interventions
Platelet Poor Plasma Tear Drops, Platelet Rich Plasma Tear Drops
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, New York
Conditions
Breast Cancer, Sarcoma, Gastric Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Genitourinary Cancer, Gynecologic Cancer, Urinary Bladder Cancer, Leukemia, Lymphoid Leukemia, Myeloma Multiple, Prostate Cancer, Pancreas Cancer, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Brain Cancer, Melanoma, Mycosis Fungoides, Kidney Cancer
Interventions
Riluzole, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California